EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project

Yrea R J van Rijt-Weetink iD, Rosanne E Huisman iD, Jan-Peter van Wieringen iD, H J M J Ineke Crijns, Florence P A M van Hunsel iD, Anneke L M Passier iD, Sander Borgsteede iD, A C G Toine Egberts iD, Laura M Yates iD, Eugène P van Puijenbroek iD

British Journal of Clinical Pharmacology · 2026

DOI: 10.1002/bcp.70615 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Clinical Pharmacology, 2026. Verfasst von Yrea R J van Rijt-Weetink und 9 weiteren Autor:innen. Beteiligte Einrichtung: Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics, University of Groningen, Groningen, The Netherlands. Hauptthemen laut MEDLINE: Information Dissemination, Pharmacovigilance, Abnormalities, Drug-Induced, Teratogens. Die Arbeit nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Innovative Medicines Initiative.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Although regulatory responses to safety signals have been studied, pregnancy‐specific data and their dissemination to medical professionals remain unclear. This study examined the characteristics and temporal trends of teratological safety signals prompting the European Medicines Agency to implement risk minimization measures. A secondary aim was to investigate how information on these signals, independent of regulatory communication, was disseminated to medical professionals in the Netherlands.

Methods

Teratological safety signals from 2002 to 2022 were retrieved from the European Pharmacovigilance Issues Tracking Tool. For each signal, we recorded the dates of market authorization, first spontaneous report, scientific publication, regulatory decision and dissemination through the Teratology Information Service (TIS) and Dutch professional journals. The source of the signal (spontaneous reports, scientific literature or otherwise) was assessed. Time intervals between events were calculated and visualized.

Results

Twenty‐four safety signals pertaining to fetal teratogenesis were identified. At the time of regulatory action, medicines had been on the market for a median of 23.9 years (range 3.2–59.3). Cases or studies published in the scientific literature were the origin for most ( n = 18, 75%) teratological safety signals. Amendments of the product information was a regulatory action for all signals; eight (33%) also triggered Direct Healthcare Professional Communications. Apart from these regulatory communications, information may have reached healthcare professionals through scientific literature or other channels, sometimes before and sometimes alongside regulatory decisions.

Conclusion

Teratological safety signals are predominantly scientific literature‐driven and often arise decades after marketing. Scientific publications and TIS may provide early guidance, frequently preceding regulatory decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Information DisseminationPharmacovigilanceAbnormalities, Drug-InducedTeratogensAdverse Drug Reaction Reporting SystemsHealth PersonnelHumansNetherlandsFemalePregnancyEuropean UnionTeratologyTeratogenesis

Stichwörter der Autor:innen

drug safetypregnancyregulatory decisionsafety signalteratology

Substanzen

Teratogens

Autor:innen und Institutionen

  • Groningen Research Institute of Pharmacy, PharmacoTherapy, -Epidemiology and -Economics, University of Groningen, Groningen, The Netherlands.
  • Medicines Evaluation Board, Utrecht, The Netherlands.
  • Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
  • Department of Clinical Decision Support, Health Base Foundation, Houten, The Netherlands.
  • Division of Pharmacoepidemiology and Clinical Pharmacology, Department of Pharmaceutical Sciences, Faculty of Science, Utrecht University, Utrecht, The Netherlands.
  • Department of Clinical Pharmacy, University Medical Centre Utrecht, Utrecht, Netherlands.

ORCID-Profile: Yrea R J van Rijt-Weetink, Rosanne E Huisman, Jan-Peter van Wieringen, Florence P A M van Hunsel, Anneke L M Passier, Sander Borgsteede, A C G Toine Egberts, Laura M Yates, Eugène P van Puijenbroek

Förderung

  • Innovative Medicines Initiative

Zitieren

APA

van Rijt-Weetink, Y. R. J., Huisman, R. E., van Wieringen, J. P., Crijns, H. J. M. J. I., van Hunsel, F. P. A. M., Passier, A. L. M., Borgsteede, S., Egberts, A. C. G. T., Yates, L. M., & van Puijenbroek, E. P. (2026). Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70615

Vancouver

van Rijt-Weetink YRJ, Huisman RE, van Wieringen JP, Crijns HJMJI, van Hunsel FPAM, Passier ALM, et al. Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project. British Journal of Clinical Pharmacology. 2026. doi:10.1002/bcp.70615

BibTeX
@article{vanRijtWeetink2026,
  author = {van Rijt-Weetink, Yrea R J and Huisman, Rosanne E and van Wieringen, Jan-Peter and Crijns, H J M J Ineke and van Hunsel, Florence P A M and Passier, Anneke L M and Borgsteede, Sander and Egberts, A C G Toine and Yates, Laura M and van Puijenbroek, Eugène P},
  title = {Characteristics and temporal trends of EU teratological safety signals and information dissemination to healthcare professionals in the Netherlands—A contribution of the ConcePTION project},
  journal = {British Journal of Clinical Pharmacology},
  year = {2026},
  doi = {10.1002/bcp.70615}
}
Kostenlos starten →